MX2011011410A - Metodos y reactivos para una transferencia genica eficaz y dirigida a monocitos y macrofagos. - Google Patents

Metodos y reactivos para una transferencia genica eficaz y dirigida a monocitos y macrofagos.

Info

Publication number
MX2011011410A
MX2011011410A MX2011011410A MX2011011410A MX2011011410A MX 2011011410 A MX2011011410 A MX 2011011410A MX 2011011410 A MX2011011410 A MX 2011011410A MX 2011011410 A MX2011011410 A MX 2011011410A MX 2011011410 A MX2011011410 A MX 2011011410A
Authority
MX
Mexico
Prior art keywords
monocytes
efficient
macrophages
reagents
methods
Prior art date
Application number
MX2011011410A
Other languages
English (en)
Inventor
Duro Miguel Angel Gassull
Fernandez Adolfo Rio
Gimeno Ester Fernandez
Rodriguez Miguel Chillon
Original Assignee
Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats filed Critical Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats
Publication of MX2011011410A publication Critical patent/MX2011011410A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un vector útil y bioseguro para transferir material genético a células mononucleares CD14+ (monocitos y macrófagos derivados de monocitos) de una manera eficaz y específica. La realización de la invención hace uso de los vectores de adenovirus 5 humano quimérico que portan la fibra corta de Ad40 enterotrópico para transferir material genético a las células mononucleares CD14+ diana.
MX2011011410A 2009-04-29 2010-04-28 Metodos y reactivos para una transferencia genica eficaz y dirigida a monocitos y macrofagos. MX2011011410A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159001A EP2248903A1 (en) 2009-04-29 2009-04-29 Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
PCT/EP2010/055739 WO2010125115A1 (en) 2009-04-29 2010-04-28 Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages

Publications (1)

Publication Number Publication Date
MX2011011410A true MX2011011410A (es) 2012-02-13

Family

ID=40971328

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011410A MX2011011410A (es) 2009-04-29 2010-04-28 Metodos y reactivos para una transferencia genica eficaz y dirigida a monocitos y macrofagos.

Country Status (13)

Country Link
US (2) US20120045389A1 (es)
EP (3) EP2248903A1 (es)
AR (1) AR081354A1 (es)
AU (2) AU2010243566A1 (es)
BR (1) BRPI1016241A2 (es)
CA (1) CA2758592C (es)
ES (1) ES2550834T3 (es)
HU (1) HUE027887T2 (es)
IL (1) IL215688A (es)
MX (1) MX2011011410A (es)
PT (1) PT2695945E (es)
UY (1) UY32592A (es)
WO (1) WO2010125115A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
CA2850380C (en) 2012-02-14 2015-08-18 Loma Linda University Agents and method for treating inflammation-related conditions and diseases
AU2014201381B2 (en) * 2012-02-14 2014-05-15 Loma Linda University Agents and method for treating inflammation-related conditions and diseases
JP6356614B2 (ja) 2012-02-17 2018-07-11 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 薬剤のミトコンドリア輸送のためのナノ粒子
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
GB201504251D0 (en) * 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
MX2022002613A (es) * 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
BR112022011339A2 (pt) * 2019-12-11 2022-10-04 Myeloid Therapeutics Inc Composições de células terapêuticas e métodos para fabricação e usos das mesmas
US20210317170A1 (en) * 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
CN115747170B (zh) * 2022-08-29 2023-08-04 四川大学 一种豇豆褪绿斑驳病毒-多肽复合物及其在骨质疏松治疗中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
NZ500791A (en) 1997-05-08 2002-10-25 Genetic Therapy Inc Gene transfer with adenoviruses having modified fiber proteins
CA2291323A1 (en) 1997-05-28 1998-12-03 Genvec, Inc. Alternatively targeted adenovirus
US20050084966A1 (en) 1999-04-20 2005-04-21 Edelson Richard L. Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CN1359391A (zh) 1999-07-06 2002-07-17 哥德－A－基因股份公司 重组腺病毒
AU2001252766A1 (en) 2000-04-26 2001-11-07 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
CA2474763A1 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
JP2007531507A (ja) * 2003-06-11 2007-11-08 ザ スクリップス リサーチ インスティテュート 効率的な受容体結合のための修飾型線維タンパク質
GR20060100496A (el) * 2006-09-01 2008-04-15 Παρθενιος Μπουλικας ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ
WO2008124483A1 (en) 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics

Also Published As

Publication number Publication date
US20150174257A1 (en) 2015-06-25
AR081354A1 (es) 2012-08-29
CA2758592A1 (en) 2010-11-04
WO2010125115A1 (en) 2010-11-04
AU2014203841B2 (en) 2016-03-31
AU2014203841A1 (en) 2014-07-31
EP2695945B9 (en) 2015-11-11
HUE027887T2 (en) 2016-10-28
UY32592A (es) 2010-11-30
US20120045389A1 (en) 2012-02-23
CA2758592C (en) 2015-12-15
AU2014203841B8 (en) 2016-09-29
PT2695945E (pt) 2015-11-16
IL215688A0 (en) 2012-01-31
AU2014203841A8 (en) 2016-09-29
IL215688A (en) 2015-09-24
BRPI1016241A2 (pt) 2015-09-01
AU2010243566A1 (en) 2011-09-15
EP2695945A1 (en) 2014-02-12
EP2248903A1 (en) 2010-11-10
EP2424998A1 (en) 2012-03-07
EP2695945B1 (en) 2015-07-22
ES2550834T3 (es) 2015-11-12

Similar Documents

Publication Publication Date Title
MX2011011410A (es) Metodos y reactivos para una transferencia genica eficaz y dirigida a monocitos y macrofagos.
MX2018008440A (es) Vectores de terapia genica y citosina deaminasas.
MX2022009512A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
MX347453B (es) Canalrodopsina 2 mutante.
IN2014DN03061A (es)
MX2012005181A (es) Metodos para la propagacion de vectores adenovirales de monos.
IN2014DN03005A (es)
IL219882A0 (en) System for increasing gene expression and vector comprising the system
HK1123313A1 (en) Methods and compositions for gene inactivation
WO2008122811A3 (en) Adenoviral vectors encoding a pathogen or tumour antigen
IL192730A0 (en) Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
EP2382318A4 (en) NEW GENE OF BACILLUS THURINGIENSIS WITH ANTI-LEPIDOPTERA ACTIVITY
ZA200905374B (en) Hepatocyctes and chondrocytes from adherent placental stem cells;and cd34+cd45-placental stem cell-enriched cell populations
GB2441488A (en) Suspension culture of human embryonic stem cells
MX2011011508A (es) Vector genico.
MX344970B (es) Medio de cultivo celular para la expresion de la proteina adamts.
ZA201004007B (en) Direct processing of metallic ore concentrates into ferroalloys
WO2007130520A3 (en) Cross-species and multi-species display systems
UA117654C2 (uk) Трансгенна рослина, яка експресує фермент, що деградує клітинну стінку, і вектор експресії
HK1119737A1 (en) Mammalian expression vector comprising the mcmv promoter and first intron of hcmv major immediate early gene
MX2011010763A (es) Promotor de planta operable en endosperma y usos del mismo.
ZA201101348B (en) Novel bacillus thuringiensis gene with lepidopteran activity
WO2009149359A3 (en) Survival predictor for diffuse large b cell lymphoma
MX2008013397A (es) Analisis de perfilamiento de expresion diferencial de fenotipos de cultivo celular y usos de los mismos.
HK1204651A1 (en) Expression vector for producing protein derived from foreign gene in large quantity using animal cells, and use thereof

Legal Events

Date Code Title Description
FG Grant or registration